B-cell malignancies can be treated with licensed antibody-based TRT radiopharmaceuticals targeting upregulated receptors including CD20, whereas neuroendocrine and prostate cancers can be treated with licensed small-molecule TRT radiopharmaceuticals targeting the somatostatin receptor and PSMA, respectively. Here, FOLH1 is linked to prostate cancer.